229 related articles for article (PubMed ID: 25695927)
1. Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics.
Kato S; Schwaederle M; Daniels GA; Piccioni D; Kesari S; Bazhenova L; Shimabukuro K; Parker BA; Fanta P; Kurzrock R
Cell Cycle; 2015; 14(8):1252-9. PubMed ID: 25695927
[TBL] [Abstract][Full Text] [Related]
2. Targeting G1/S phase cell-cycle genomic alterations and accompanying co-alterations with individualized CDK4/6 inhibitor-based regimens.
Kato S; Okamura R; Adashek JJ; Khalid N; Lee S; Nguyen V; Sicklick JK; Kurzrock R
JCI Insight; 2021 Jan; 6(1):. PubMed ID: 33427211
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention.
Lowery MA; Ptashkin R; Jordan E; Berger MF; Zehir A; Capanu M; Kemeny NE; O'Reilly EM; El-Dika I; Jarnagin WR; Harding JJ; D'Angelica MI; Cercek A; Hechtman JF; Solit DB; Schultz N; Hyman DM; Klimstra DS; Saltz LB; Abou-Alfa GK
Clin Cancer Res; 2018 Sep; 24(17):4154-4161. PubMed ID: 29848569
[No Abstract] [Full Text] [Related]
4. Results of immunohistochemical staining of cell-cycle regulators: the prediction of recurrence of functioning pituitary adenoma.
Lee EH; Kim KH; Kwon JH; Kim HD; Kim YZ
World Neurosurg; 2014; 81(3-4):563-75. PubMed ID: 24067736
[TBL] [Abstract][Full Text] [Related]
5. Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course.
Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T
Clin Cancer Res; 2003 Oct; 9(13):4884-90. PubMed ID: 14581362
[TBL] [Abstract][Full Text] [Related]
6. Involvement of ERK1/2, p38 MAPK, and PI3K/Akt signaling pathways in the regulation of cell cycle progression by PTHrP in colon adenocarcinoma cells.
Calvo N; Martín MJ; de Boland AR; Gentili C
Biochem Cell Biol; 2014 Aug; 92(4):305-15. PubMed ID: 25051885
[TBL] [Abstract][Full Text] [Related]
7. Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC.
Kim Y; Lee B; Shim JH; Lee SH; Park WY; Choi YL; Sun JM; Ahn JS; Ahn MJ; Park K
J Thorac Oncol; 2019 Feb; 14(2):193-202. PubMed ID: 30391576
[TBL] [Abstract][Full Text] [Related]
8. Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy.
Kong Y; Sheng X; Wu X; Yan J; Ma M; Yu J; Si L; Chi Z; Cui C; Dai J; Li Y; Yu H; Xu T; Tang H; Tang B; Mao L; Lian B; Wang X; Yan X; Li S; Guo J
Clin Cancer Res; 2017 Nov; 23(22):6946-6957. PubMed ID: 28830923
[No Abstract] [Full Text] [Related]
9. Mechanisms of resistance to cyclin-dependent kinase 4/6 inhibitors.
Gomatou G; Trontzas I; Ioannou S; Drizou M; Syrigos N; Kotteas E
Mol Biol Rep; 2021 Jan; 48(1):915-925. PubMed ID: 33409716
[TBL] [Abstract][Full Text] [Related]
10. Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor Drugs.
Green JL; Okerberg ES; Sejd J; Palafox M; Monserrat L; Alemayehu S; Wu J; Sykes M; Aban A; Serra V; Nomanbhoy T
Mol Cancer Ther; 2019 Apr; 18(4):771-779. PubMed ID: 30837298
[TBL] [Abstract][Full Text] [Related]
11. Genomic landscape of gliosarcoma: distinguishing features and targetable alterations.
Zaki MM; Mashouf LA; Woodward E; Langat P; Gupta S; Dunn IF; Wen PY; Nahed BV; Bi WL
Sci Rep; 2021 Sep; 11(1):18009. PubMed ID: 34504233
[TBL] [Abstract][Full Text] [Related]
12. Evidence for a CDK4-dependent checkpoint in a conditional model of cellular senescence.
Brookes S; Gagrica S; Sanij E; Rowe J; Gregory FJ; Hara E; Peters G
Cell Cycle; 2015; 14(8):1164-73. PubMed ID: 25695870
[TBL] [Abstract][Full Text] [Related]
13. Genes associated with increased brain metastasis risk in non-small cell lung cancer: Comprehensive genomic profiling of 61 resected brain metastases versus primary non-small cell lung cancer (Guangdong Association Study of Thoracic Oncology 1036).
Wang H; Ou Q; Li D; Qin T; Bao H; Hou X; Wang K; Wang F; Deng Q; Liang J; Zheng W; Wu X; Wang X; Shao YW; Mou Y; Chen L
Cancer; 2019 Oct; 125(20):3535-3544. PubMed ID: 31287555
[TBL] [Abstract][Full Text] [Related]
14. Implications of Genetic and Epigenetic Alterations of CDKN2A (p16(INK4a)) in Cancer.
Zhao R; Choi BY; Lee MH; Bode AM; Dong Z
EBioMedicine; 2016 Jun; 8():30-39. PubMed ID: 27428416
[TBL] [Abstract][Full Text] [Related]
15. Frequent disruption of the RB1 pathway in diffuse large B cell lymphoma: prognostic significance of E2F-1 and p16INK4A.
Møller MB; Kania PW; Ino Y; Gerdes AM; Nielsen O; Louis DN; Skjødt K; Pedersen NT
Leukemia; 2000 May; 14(5):898-904. PubMed ID: 10803523
[TBL] [Abstract][Full Text] [Related]
16. Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancer.
Schwaederle M; Daniels GA; Piccioni DE; Kesari S; Fanta PT; Schwab RB; Shimabukuro KA; Parker BA; Kurzrock R
Cell Cycle; 2015; 14(11):1730-7. PubMed ID: 25928476
[TBL] [Abstract][Full Text] [Related]
17. Adenovirus-mediated overexpression of p15INK4B inhibits human glioma cell growth, induces replicative senescence, and inhibits telomerase activity similarly to p16INK4A.
Fuxe J; Akusjärvi G; Goike HM; Roos G; Collins VP; Pettersson RF
Cell Growth Differ; 2000 Jul; 11(7):373-84. PubMed ID: 10939591
[TBL] [Abstract][Full Text] [Related]
18. Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells.
Reiter FP; Denk G; Ziesch A; Ofner A; Wimmer R; Hohenester S; Schiergens TS; Spampatti M; Ye L; Itzel T; Munker S; Teufel A; Gerbes AL; Mayerle J; De Toni EN
Cell Oncol (Dordr); 2019 Oct; 42(5):705-715. PubMed ID: 31250364
[TBL] [Abstract][Full Text] [Related]
19. TP53 and CDKN2a mutations in never-smoker oral tongue squamous cell carcinoma.
Heaton CM; Durr ML; Tetsu O; van Zante A; Wang SJ
Laryngoscope; 2014 Jul; 124(7):E267-73. PubMed ID: 24431303
[TBL] [Abstract][Full Text] [Related]
20. Direct modulation of rheumatoid inflammatory mediator expression in retinoblastoma protein-dependent and -independent pathways by cyclin-dependent kinase 4/6.
Nonomura Y; Nagasaka K; Hagiyama H; Sekine C; Nanki T; Tamamori-Adachi M; Miyasaka N; Kohsaka H
Arthritis Rheum; 2006 Jul; 54(7):2074-83. PubMed ID: 16802342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
